Assessment of clinical performance without adequate analytical validation: A prescription for confusion

被引:13
作者
Oliver, Lawrence K. [1 ]
Voskoboev, Nikolay [1 ]
Heser, Don [1 ]
McConnell, Joseph P. [2 ]
Hodel-Hanson, Shannon [1 ]
Callanan, Heidi [1 ]
Jaffe, Allan S. [1 ,3 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55902 USA
[2] Hlth Diagnost Labs, Rochester, MN USA
[3] Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55902 USA
关键词
Phospholipase; Cardiac risk assessment; Stability; Automation; Traceability; Reference range; PHOSPHOLIPASE A(2); RISK; DISEASE;
D O I
10.1016/j.clinbiochem.2011.07.005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Lp-PLA2 is a biomarker with promise for predicting cardiac risk. The lack of reproducible results has limited its use. In evaluating a new reagent kit, we investigated conditions for optimal reproducibility. Methods: The Auto-PLAC reagents were evaluated on the Cobas instrument. Performance characteristics, stability, and population ranges were determined. Results: Analytical performance characteristics replicated manufacturer's claims. The stability profile of the analyte was unusual, with increasing results observed with storage at 4 degrees C or -20 degrees C. Only storage at -70 degrees C gave acceptable stability. Population median values with properly preserved samples were much lower than the cut off previously validated for increased risk. Conclusions: It is postulated that variability in specimen handling was a major contributor to the lack of traceability of the current reagents to the earlier clinical studies demonstrating its utility. We are now unsure how to identify reliable criteria for result interpretation. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1247 / 1252
页数:6
相关论文
共 9 条
[1]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[2]   Should soluble CD40 ligand be measured from serum or plasma samples? [J].
Bereczki, D ;
Nagy, E ;
Pál, A ;
Magyar, MT ;
Balla, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (06) :1129-1130
[3]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[4]   Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines [J].
Davidson, Michael H. ;
Corson, Marshall A. ;
Alberts, Mark J. ;
Anderson, Jeffrey L. ;
Gorelick, Philip B. ;
Jones, Peter H. ;
Lerman, Amir ;
McConnell, Joseph P. ;
Weintraub, Howard S. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A) :51F-57F
[5]   Variability of lipoprotein-associated phospholipase A2 measurements [J].
McConnell, Joseph P. ;
Jaffe, Allan S. .
CLINICAL CHEMISTRY, 2008, 54 (05) :932-933
[6]   Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. [J].
Packard, CJ ;
O'Reilly, DSJ ;
Caslake, MJ ;
McMahon, AD ;
Ford, I ;
Cooney, J ;
Macphee, CH ;
Suckling, KE ;
Krishna, M ;
Wilkinson, FE ;
Rumley, A ;
Lowe, GDO .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1148-1155
[7]   Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations [J].
Shih, Jessie ;
Datwyler, Saul A. ;
Hsu, Stephen C. ;
Matias, Matthew S. ;
Pacenti, David P. ;
Lueders, Christian ;
Mueller, Christian ;
Danne, Oliver ;
Moeckel, Martin .
CLINICAL CHEMISTRY, 2008, 54 (06) :1076-1079
[8]   Lipoprotein-associated phospholipase A(2), vascular inflammation and cardiovascular risk prediction [J].
Sudhir, Krishnankutty .
VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (02) :153-156
[9]  
Thompson A, 2010, LANCET, V375, P1536, DOI 10.1016/S0140-6736(10)60319-4